TY  - JOUR
AU  - Mijatović, Sanja
AU  - Bulatović, Mirna Z.
AU  - Mojić, Marija
AU  - Stošić-Grujičić, Stanislava
AU  - Miljković, Đorđe
AU  - Maksimović-Ivanić, Danijela
AU  - Gomez-Ruiz, Santiago
AU  - Pinkas, Jiri
AU  - Horacek, Michal
AU  - Kaluđerović, Goran N.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2247
AB  - The previously known complexes {[}Ti\{(Me2CMe2C)(eta(5)-C5H4)(2)\}Cl-2]
   (1), {[}Ti\{Me2C(eta(5)-C5H4)(2)\}Cl-2] (2), {[}Ti
   \{Me2Si(eta(5)-C5H4)(2)\}Cl-2] (4), {[}Ti\{MePhSi(eta(5)-C5H4)(2)\}Cl-2]
   (5) and {[}Ti\{MePhSi(eta(5)-C5Me4)(2)\}Cl-2] (6) have been prepared
   following reported procedures. The novel complex
   {[}Ti\{MePhC(eta(5)-C5H4)(2)\}Cl-2] (3) has been prepared and
   characterized. The cytotoxic activity of 1-6 has been tested after 72 h
   on melanoma A375 and B16, prostate cancer DU145 and LNCaP and colon
   cancer HCT116, SW620 and CT26CL25 cell lines observing a high cytotoxic
   activity of complexes 1 and 6 compared to the reference compound
   ({[}Ti(eta(5)-C5H5)(2)\}Cl-2]). 1 and 6 have also been tested against
   primary normal mouse keratinocytes and lung fibroblasts. While viability
   of both type of primary cells was significantly less affected by 1 in
   comparison to the reference compound {[}Ti(eta(5)-C5H5)(2)Cl-2],
   compound 6 was completely nontoxic for nonmalignant cells, indicating a
   potential selectivity of this compound towards cancer cell lines. In
   addition CFSE staining, cell cycle analysis, AnnexinV-FITC/PI staining,
   detection of caspase activity and mitochondrial potential showed that 1
   and 6 were acting through inhibition of proliferation and subsequent
   induction of mitochondrial dependent apoptosis in colon cancer cell
   lines, HCT116 and SW620, which express low sensitivity to cisplatin.
   Compound 6 was found to be the leading drug in this group since it shows
   the fastest and most selective anticancer profile. (C) 2013 Elsevier
   B.V. All rights reserved.
T2  - Journal of Organometallic Chemistry
T1  - Study of the anticancer properties of methyl- and phenyl-substituted
 carbon- and silicon-bridged ansa-titanocene complexes
VL  - 751
DO  - 10.1016/j.jorganchem.2013.07.059
SP  - 361
EP  - 367
ER  - 

@article{
author = "Mijatović, Sanja and Bulatović, Mirna Z. and Mojić, Marija and Stošić-Grujičić, Stanislava and Miljković, Đorđe and Maksimović-Ivanić, Danijela and Gomez-Ruiz, Santiago and Pinkas, Jiri and Horacek, Michal and Kaluđerović, Goran N.",
year = "2014",
abstract = "The previously known complexes {[}Ti\{(Me2CMe2C)(eta(5)-C5H4)(2)\}Cl-2]
   (1), {[}Ti\{Me2C(eta(5)-C5H4)(2)\}Cl-2] (2), {[}Ti
   \{Me2Si(eta(5)-C5H4)(2)\}Cl-2] (4), {[}Ti\{MePhSi(eta(5)-C5H4)(2)\}Cl-2]
   (5) and {[}Ti\{MePhSi(eta(5)-C5Me4)(2)\}Cl-2] (6) have been prepared
   following reported procedures. The novel complex
   {[}Ti\{MePhC(eta(5)-C5H4)(2)\}Cl-2] (3) has been prepared and
   characterized. The cytotoxic activity of 1-6 has been tested after 72 h
   on melanoma A375 and B16, prostate cancer DU145 and LNCaP and colon
   cancer HCT116, SW620 and CT26CL25 cell lines observing a high cytotoxic
   activity of complexes 1 and 6 compared to the reference compound
   ({[}Ti(eta(5)-C5H5)(2)\}Cl-2]). 1 and 6 have also been tested against
   primary normal mouse keratinocytes and lung fibroblasts. While viability
   of both type of primary cells was significantly less affected by 1 in
   comparison to the reference compound {[}Ti(eta(5)-C5H5)(2)Cl-2],
   compound 6 was completely nontoxic for nonmalignant cells, indicating a
   potential selectivity of this compound towards cancer cell lines. In
   addition CFSE staining, cell cycle analysis, AnnexinV-FITC/PI staining,
   detection of caspase activity and mitochondrial potential showed that 1
   and 6 were acting through inhibition of proliferation and subsequent
   induction of mitochondrial dependent apoptosis in colon cancer cell
   lines, HCT116 and SW620, which express low sensitivity to cisplatin.
   Compound 6 was found to be the leading drug in this group since it shows
   the fastest and most selective anticancer profile. (C) 2013 Elsevier
   B.V. All rights reserved.",
journal = "Journal of Organometallic Chemistry",
title = "Study of the anticancer properties of methyl- and phenyl-substituted
 carbon- and silicon-bridged ansa-titanocene complexes",
volume = "751",
doi = "10.1016/j.jorganchem.2013.07.059",
pages = "361-367"
}

Mijatović, S., Bulatović, M. Z., Mojić, M., Stošić-Grujičić, S., Miljković, Đ., Maksimović-Ivanić, D., Gomez-Ruiz, S., Pinkas, J., Horacek, M.,& Kaluđerović, G. N.. (2014). Study of the anticancer properties of methyl- and phenyl-substituted
 carbon- and silicon-bridged ansa-titanocene complexes. in Journal of Organometallic Chemistry, 751, 361-367.
https://doi.org/10.1016/j.jorganchem.2013.07.059

Mijatović S, Bulatović MZ, Mojić M, Stošić-Grujičić S, Miljković Đ, Maksimović-Ivanić D, Gomez-Ruiz S, Pinkas J, Horacek M, Kaluđerović GN. Study of the anticancer properties of methyl- and phenyl-substituted
 carbon- and silicon-bridged ansa-titanocene complexes. in Journal of Organometallic Chemistry. 2014;751:361-367.
doi:10.1016/j.jorganchem.2013.07.059 .

Mijatović, Sanja, Bulatović, Mirna Z., Mojić, Marija, Stošić-Grujičić, Stanislava, Miljković, Đorđe, Maksimović-Ivanić, Danijela, Gomez-Ruiz, Santiago, Pinkas, Jiri, Horacek, Michal, Kaluđerović, Goran N., "Study of the anticancer properties of methyl- and phenyl-substituted
 carbon- and silicon-bridged ansa-titanocene complexes" in Journal of Organometallic Chemistry, 751 (2014):361-367,
https://doi.org/10.1016/j.jorganchem.2013.07.059 . .